Sonya Reid

Has grant

Vanderbilt University Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Vanderbilt Training Program in Molecular and Genetic Epidemiology of Cancer

Open Date: 2017-09-01

Close Date: 2022-08-31

Articles (12)

Purpose: Circulating tumor cells (CTC) are biomarkers associated with poor prognosis and treatment resistance in hormone receptor–positive (HR+)/HER2-negative metastatic breast cancer (MBC). This analysis evaluates the prognostic role of baseline CTC enumeration and its interaction with treatment regimens in patients progressing on CDK4/6 inhibitors. Experimental Design: The PACE trial is a phase II, multicenter, randomized study of patients with HR+/HER2− MBC experiencing progression on aromatase inhibitors and CDK4/6 inhibitors. Patients were randomized 1:2:1 to receive fulvestrant (F), F + palbociclib (F + P), or F + P + avelumab (F + P + A). Baseline CTCs were enumerated using CellSearch with a threshold of ≥5 CTCs/7.5 mL to classify patients as stage IV indolent or stage IV aggressive . Concurrent ctDNA analysis was performed using Guardant360. Progression-free survival (PFS) was the primary endpoint. Results: Among 220 randomly assigned patients, 203 were evaluable for baseline CTCs; 76% had detectable CTCs and 49% were stage IV aggressive . Patients with de novo MBC were more frequently stage IV aggressive (47.5% vs. 30.8%). Baseline CTCs were prognostic with median PFS of 5.7 months for stage IV indolent and 3.5 months for stage IV aggressive patients [HR = 1.69; 90% confidence interval (CI), 1.27–2.24; P aggressive patients, F + P and F + P + A improved PFS versus fulvestrant alone (HR = 0.43; 90% CI, 0.25–0.71 and HR = 0.26; 90% CI, 0.14–0.49, respectively). No benefit was observed in stage IV indolent patients (interaction P = 0.0148 and P = 0.0033, respectively). Conclusions: Baseline CTC enumeration provides significant prognostic information in HR+/HER2− MBC. Stage IV aggressive patients derive greater benefit from F + P or F + P + A over fulvestrant alone, independent of clinical or ctDNA features. This highlights the potential of CTCs to guide treatment decision-making.

Year:

2025

Multivariable Cox regression in terms of PFS. CTCs enumeration was corrected for ESR1, PIK3CA, RB1 mutational status and clinically relevant features (i.e., visceral involvement, duration of prior CDK4/6 inhibitor, endocrine sensitivity, therapy between prior CDK4/6i and randomization).

Year:

2025

PACE Trial Schema. Total planned enrollment was 220 patients. Primary objective: superiority of fulvestrant+palbociclib vs fulvestrant alone (A). Secondary objective: superiority fulvestrant+palbociclib+avelumab vs fulvestrant alone (B).

Year:

2025

Supplementary Figure 2: MHC-I and MHC-II expression is higher in Stage I/II, premenopausal patients. The relative frequency difference of tumors having (A) high MHC-I expression and (B) ≥ 5% tumor cells expressing MHC-II are compared between stage and menopausal status . Relative frequency difference calculated using Stage I/II and premenopausal as control condition, with negative RFD representing frequency higher in Stage I/II or premenopausal patients. Bootstrap method used to generate standard errors.

Year:

2024

Purpose: Immunotherapy (IO) in triple-negative breast cancer (TNBC) has improved survival outcomes, with promising improvements in pCR rates among early high-risk hormone receptor (HR)+/HER2− breast cancers. However, biomarkers are needed to select patients likely to benefit from IO. MHC-I and tumor-specific MHC-II (tsMHC-II) expression are candidate biomarkers for PD-(L)1 checkpoint inhibition but existing data from clinical trials included limited racial/ethnic diversity. Experimental Design: We performed multiplexed immunofluorescence assays in the Carolina Breast Cancer Study (CBCS; n = 1,628, 48% Black, 52% non-Black). Intrinsic subtype and P53 mutant-like status were identified using RNA-based multigene assays. We ranked participants based on tumoral MHC-I intensity (top 33% categorized as “MHC-I h igh ”) and MHC-II+ (≥5% of tumor cells as tsMHC-II+). MHC-I/II were evaluated in association with clinicopathological features by race. Results: Black participants had higher frequency of TNBC (25% vs. 12.5%, P ≤ 0.001) and basal-like (30% vs. 14%, P ≤ 0.001) tumors overall, and higher frequency of basal-like (11% vs. 5.5%, P = 0.002) and TP53 mutant tumors (26% vs. 17%, P = 0.002) among HR+/HER2−. The frequency of tsMHC-II+ was higher in HR+/HER2− Black participants (7.9% vs. 4.9%, P = 0.04). Black participants also had higher frequency of MHC-I high (38.7% vs. 28.2%, P P = 0.02). Conclusions: In this diverse study population, MHC-I and MHC-II tumor cell expression were more highly expressed in HR+/HER2− tumors from Black women, underscoring the importance of diverse and equitable enrollment in future IO trials.

Year:

2024

Supplementary Figure 1: MHC-I and MHC-II expression is associated with Race. The log10(n+1) normalized (A) percentage of MHC-I+ tumor cells and (B) percentage of MHC-II+ tumor cells are compared between Black and Non-Black patients. Student t-test was used.

Year:

2024

Supplementary Figure 2: MHC-I and MHC-II expression is higher in Stage I/II, premenopausal patients. The relative frequency difference of tumors having (A) high MHC-I expression and (B) ≥ 5% tumor cells expressing MHC-II are compared between stage and menopausal status . Relative frequency difference calculated using Stage I/II and premenopausal as control condition, with negative RFD representing frequency higher in Stage I/II or premenopausal patients. Bootstrap method used to generate standard errors.

Year:

2024

Supplementary Figure 1: MHC-I and MHC-II expression is associated with Race. The log10(n+1) normalized (A) percentage of MHC-I+ tumor cells and (B) percentage of MHC-II+ tumor cells are compared between Black and Non-Black patients. Student t-test was used.

Year:

2024

Purpose: Immunotherapy (IO) in triple-negative breast cancer (TNBC) has improved survival outcomes, with promising improvements in pCR rates among early high-risk hormone receptor (HR)+/HER2− breast cancers. However, biomarkers are needed to select patients likely to benefit from IO. MHC-I and tumor-specific MHC-II (tsMHC-II) expression are candidate biomarkers for PD-(L)1 checkpoint inhibition but existing data from clinical trials included limited racial/ethnic diversity. Experimental Design: We performed multiplexed immunofluorescence assays in the Carolina Breast Cancer Study (CBCS; n = 1,628, 48% Black, 52% non-Black). Intrinsic subtype and P53 mutant-like status were identified using RNA-based multigene assays. We ranked participants based on tumoral MHC-I intensity (top 33% categorized as “MHC-I h igh ”) and MHC-II+ (≥5% of tumor cells as tsMHC-II+). MHC-I/II were evaluated in association with clinicopathological features by race. Results: Black participants had higher frequency of TNBC (25% vs. 12.5%, P ≤ 0.001) and basal-like (30% vs. 14%, P ≤ 0.001) tumors overall, and higher frequency of basal-like (11% vs. 5.5%, P = 0.002) and TP53 mutant tumors (26% vs. 17%, P = 0.002) among HR+/HER2−. The frequency of tsMHC-II+ was higher in HR+/HER2− Black participants (7.9% vs. 4.9%, P = 0.04). Black participants also had higher frequency of MHC-I high (38.7% vs. 28.2%, P P = 0.02). Conclusions: In this diverse study population, MHC-I and MHC-II tumor cell expression were more highly expressed in HR+/HER2− tumors from Black women, underscoring the importance of diverse and equitable enrollment in future IO trials.

Year:

2024

Year:

2020

Year:

2020

Year:

2020

Collaborators (16)

Carolina Reduzzi

Assistant Professor

Weill Cornell Medicine

UNITED STATES
View details

Priyanka Sharma

Associate Professor

University of Kansas Medical Center

UNITED STATES
View details

Charles Perou

Professor

University of North Carolina

UNITED STATES
View details

Laura Kennedy

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Angela DeMichele

University of Pennsylvania

UNITED STATES
View details

Justin M. Balko

Vanderbilt University Medical Center

UNITED STATES
View details

Cynthia X. Ma

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Yara G Abdou

University of North Carolina at Chapel Hill

UNITED STATES
View details

Harold Burstein

Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Xiaopeng Sun

Vanderbilt University

UNITED STATES
View details

Melissa A. Troester

Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Rubina Qamar

Associate Professor

University of Wisconsin-Madison Carbone Cancer Center

UNITED STATES
View details

Kathy Miller

Indiana University Bloomington

UNITED STATES
View details

Erica Mayer

Dana-Farber Cancer Institute

UNITED STATES
View details

Massimo Cristofanilli

Professor of Medicine

Weill Cornell Medicine

UNITED STATES
View details

Reshma Mahtani

Chief of Breast Medical Oncology

Sylvester Comprehensive Cancer Center, University of Miami

UNITED STATES
View details